Overview
Aspirin (acetylsalicylic acid) is a non-steroidal anti-inflammatory drug (NSAID) that irreversibly inhibits cyclooxygenase (COX) enzymes, suppressing prostaglandin synthesis. While widely used as an antiplatelet and anti-inflammatory agent, aspirin carries significant implications for the gut microbiome and intestinal barrier integrity.
COX inhibition reduces protective prostaglandin production in the gastrointestinal mucosa, predisposing to NSAID enteropathy — a condition characterized by increased intestinal permeability, mucosal erosion, and shifts in microbial community composition (wang 2021 gut microbiota nsaid enteropathy). The resulting barrier damage can facilitate bacterial translocation and low-grade endotoxemia.
Aspirin use has also been examined in the context of neurological conditions. Epidemiological data link NSAID exposure patterns to altered microbiome profiles in Parkinson's disease cohorts (nsaids 2023 parkinsons microbiome), and aspirin appears alongside other pharmaceutical exposures (acetaminophen, amoxicillin) as a variable in autism-spectrum microbiome research (good 2018 acetaminophen amoxicillin glyphosate autism).
Cross-References
- nutritional immunity — prostaglandin-mediated mucosal defense overlaps with innate barrier functions
- gut barrier — COX inhibition directly compromises barrier integrity
- parkinsons disease — NSAID-microbiome associations in neurodegeneration
- autism spectrum disorder — pharmaceutical exposure and microbiome disruption